

## Free-Living Monitoring of Parkinson's Disease: Lessons From the Field

Silvia Del Din, PhD,<sup>1</sup> Alan Godfrey, PhD,<sup>1</sup> Claudia Mazzà, PhD,<sup>2,3</sup> Sue Lord, PhD,<sup>1</sup> and Lynn Rochester, PhD<sup>1\*</sup><sup>1</sup>*Institute of Neuroscience, Newcastle University Institute for Ageing, Clinical Ageing Research Unit, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK*<sup>2</sup>*Department of Mechanical Engineering, The University of Sheffield, Sheffield, UK*<sup>3</sup>*INSIGNEO Institute for In Silico Medicine, The University of Sheffield, Sheffield, UK*

**ABSTRACT:** Wearable technology comprises miniaturized sensors (eg, accelerometers) worn on the body and/or paired with mobile devices (eg, smart phones) allowing continuous patient monitoring in unsupervised, habitual environments (termed free-living). Wearable technologies are revolutionizing approaches to health care as a result of their utility, accessibility, and affordability. They are positioned to transform Parkinson's disease (PD) management through the provision of individualized, comprehensive, and representative data. This is particularly relevant in PD where symptoms are often triggered by task and free-living environmental challenges that cannot be replicated with sufficient veracity elsewhere. This review concerns use of wearable technology in free-living environments for people with PD. It outlines the potential advantages of wearable technologies and evidence for these to accurately detect and measure clinically relevant features including motor symptoms, falls risk, freezing of gait, gait, functional mobility, and physical activity. Technological limitations

and challenges are highlighted, and advances concerning broader aspects are discussed. Recommendations to overcome key challenges are made. To date there is no fully validated system to monitor clinical features or activities in free-living environments. Robust accuracy and validity metrics for some features have been reported, and wearable technology may be used in these cases with a degree of confidence. Utility and acceptability appears reasonable, although testing has largely been informal. Key recommendations include adopting a multidisciplinary approach for standardizing definitions, protocols, and outcomes. Robust validation of developed algorithms and sensor-based metrics is required along with testing of utility. These advances are required before widespread clinical adoption of wearable technology can be realized. © 2016 International Parkinson and Movement Disorder Society

**Key Words:** wearable technology; Parkinson's disease; remote monitoring; free-living assessment

Wearable technology and connected devices (WTCD) are positioned to become ubiquitous in research and healthcare settings. WTCD comprise electronic technology worn on the body or embedded into mobile phones, watches, bracelets, and clothing among others. The generic appeal of WTCD is obvious. Patient monitoring is free from contextual or environment barriers, making assessment at home and in the community over continuous time periods

(termed *free living*) feasible and ecologically valid.<sup>1</sup> Moreover, data are free from the confounds of observer bias and attentional compensation associated with a one-off testing session under observation,<sup>2</sup> and devices are relatively low cost, making their use economically as well as practically feasible.

The benefits of remote monitoring with WTCD are multifold. Clinically, continuous monitoring of symptom severity and therapeutic response provides nuanced assessment. A complete picture of disease burden is available both to the clinician and the patient, incorporating a broad range of features from the micro level of detail (eg, disease symptoms, medication response and fluctuations, gait characteristics, turning, frequency of falls) to more macro levels (eg, habitual patterns of walking or activity, inactivity, and sleep; Fig. 1). Enriched measurement, coupled with ease of use, also has implications for industry, paving


\*Correspondence to: Dr. Lynn Rochester, Clinical Ageing Research Unit, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, NE4 5PL, UK; lynn.rochester@ncl.ac.uk

**Relevant conflicts of interests/financial disclosures:** Nothing to report.


**Received:** 4 February 2016; **Revised:** 9 June 2016; **Accepted:** 13 June 2016

Published online 25 July 2016 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.26718


## MACRO




C) Lying to sit transition




D) Sit to stand transition




E) Short bouts of walking/shuffling




F) Continuous walking



G) Sit to walk transition and turn



H) Festination and FOG preceding a fall



## MICRO

**FIG. 1.** Use of wearable technology and connected devices (WTCD; adapted with permission from previous work).<sup>47</sup> (A) Macro-level quantification of activities over an extended period of time (volume, patterns, and variability); (B) bouts of activities (eg, lying [sleeping], walking, sitting); (C–H) micro-level quantification from specific events: postural transitions (C and D), shuffling (E), gait (F), turning (G), freezing of gait (FOG) and fall (H).

the way for identification of early disease with the potential for enhanced diagnostic and progression markers (fundamental for trials of novel therapeutics and disease-modifying therapies), harmonization of outcomes, and standardized testing protocols to enhance recruitment and assessment of treatments in clinical trials. For the patient, WTCD offer insight into symptoms, therapeutic efficacy, and habitual mobility in the context of everyday life, contributing to enhanced self-management that is bespoke and contextualized.

Despite the recent explosion of low-cost commercially available devices (for the general population) promoting personal monitoring and feedback, the application of WTCD in healthcare has not yet been established.<sup>3</sup> The lure of utility (ie, ease of use, broad application, and low cost) is strong; however, standards for clinical adoption and research application are far higher. Although technology and design have advanced, algorithm development and data analysis have not kept pace. Validity and reliability are paramount and inform accurate detection and monitoring of disease, and this next step is critical before widespread adoption.<sup>4</sup> Although there are promising signs, there is still no single system or gold standard being used for remote monitoring.<sup>5,6</sup> Therein lies both the opportunity and the challenge.

This article considers issues related to free-living monitoring from predominantly single sensor-based devices (eg, accelerometers, gyroscopes). We examine the ability of WCTD algorithms to accurately detect a range of clinical features and report on criterion and discriminative validity of outcomes derived from WCTD. Utility and feasibility are also considered. Clinical features include the monitoring of motor symptoms, medication response, sleep, falls and falls risk, freezing of gait (FOG), gait, functional mobility, and physical activity (ambulatory activity and sedentary behavior). This rapidly expanding field and has been the subject of a number of recent systematic reviews,<sup>7-9</sup> including Sánchez-Ferro and colleagues (in this issue and to which the reader is referred). We have therefore adopted a broader approach and provide a structured overview of the current status of continuous patient monitoring in the home and community in Parkinson's disease (PD), which we define as *free living*. We address the following four key aims: (1) the role and benefits of free-living monitoring, (2) the validity and utility (acceptability and feasibility) of WCTD to monitor a range of key clinical features relevant to PD, (3) critical challenges for adoption of WCTD for free-living assessment, and (4) future developments in this rapidly developing field. Throughout the article, we focus mainly on the application of passive (no interaction from patient) single sensor-based devices and their application in PD, but where

relevant draw from work in aging cohorts. Finally, we make recommendations based on this overview to progress free-living monitoring in PD.

## Does Free-Living Monitoring Confer an Advantage Over Clinical Assessment in PD?







Because of its heterogeneity and complexity, clinical assessment of PD is challenging. The intrinsic, fluctuating nature of PD and biphasic medication response in advanced disease requires continuous evaluation for prolonged periods of time to gain an accurate picture of symptoms and their fluctuations. The influence of attention on performance is well recognized, especially with symptoms such as FOG, leading to an inaccurate clinical picture.<sup>2,8</sup> Assessments requiring concentration and recall such as fall diaries are further compromised by cognitive impairment, thus limiting utility. Also, the use of clinical scales is restrictive. The Unified Parkinson's Disease Rating Scale (UPDRS),<sup>10</sup> although highly relevant to PD, is dependent on the patient's status at the time of assessment and limited by subjectivity and clinical expertise. WCTD overcome many of these limitations by objectively quantifying clinically relevant outcomes. Variation in testing is reduced.<sup>3,11,12</sup> Patients also have much to gain from this approach, with less emphasis during clinical visits on symptom recall and evaluation of therapeutic response. Continuous monitoring also provides greater potential for patient involvement in defining optimal management.<sup>12</sup>

Measurement with WCTD is diverse. A single WCTD has the potential to provide the clinician or researcher with a comprehensive picture of their patient within 1 assessment. For example, Figure 1 shows that the placement of a single sensor can quantify features such as volume and pattern of habitual behaviors (eg, walking, sleeping, sedentary time [Fig. 1A], defined here as *macro*). The raw signal (Fig. 1B) can then be further broken down to detect very discrete features (eg, a fall, gait characteristics, turning and freezing [Fig. 1C-H]; defined here as *micro*). Taking this approach enables multilevel measurement.<sup>13</sup>

## Free-Living Assessment of Clinically Relevant Features in PD: A Valid Alternative to Conventional Clinical Assessment?













Despite the obvious advantages of free-living assessment the following important questions remain: Are the outcome measures derived from WCTD suitable for current clinical use, and will patients and

**TABLE 1.** Studies examining free-living monitoring of Parkinson's disease (PD) using wearable technology and connected devices (WTCD)

								
Study (year), N, length of recording	WTCD and placement	Clinical feature/activity	Accurate detection of clinical feature: method of appraisal <sup>a</sup>	Measures	Criterion validity <sup>a</sup>	Discriminative validity <sup>a</sup>	Utility	
<b>Motor symptoms and medication response</b>								
Das et al (2012) <sup>21</sup> , 2 PD, 4 <sup>b</sup>		Dyskinesia, tremor	Yes, against patients' diaries using weakly supervised machine learning technique.	Acceleration derived features (Mean energy, high frequency energy content, correlation, frequency domain entropy)	No	No	No	
Griffiths et al (2012) <sup>18</sup> , 34 PD/10 OA, 10		Bradykinesia, dyskinesia	Yes, for bradykinesia against dot slide task measure (specificity 88%, sensitivity 95%) during scripted tests.	Acceleration derived features: Mean Spectral Power within specific bands, peak, amount of time with no movement	Yes, dyskinesia against the AIMS score and both dyskinesia and bradykinesia against UPDRS III and IV	No	No	
Mera et al (2012) <sup>19</sup> , 10 PD/10 OA, 3-6		Motor tasks, tremor, bradykinesia, motor fluctuations	No	Symptoms severity scale (0-4 points), voluntary movement threshold evaluated with gyroscope derived features (RMS, peak of power spectrum)	Yes, for tremor and bradykinesia. Potential issues of recognition when the 2 symptoms overlap. Yes against videos in the lab for symptom severity scale validated against UPDRS tremor and MBRS speed, amplitude and rhythm scores in previous work <sup>75,92</sup>	No	Yes, formal testing previous work <sup>75</sup>	
Pastorino et al (2013) <sup>17</sup> , 2 PD, 7 (but 32 hours analyzed)		Akinesia, ON/OFF state	Yes, "proof of concept" validation against patients' diaries	Level of akinesia	No	No	Yes, formal testing	
Tzallas et al (2014) <sup>22</sup> , 12 PD, 5 (8 hours per day)		Tremor, LID, Bradykinesia, FOG	Yes, in the lab and during structured test (eg, for FOG events opening door/straight 10-minute walking) against video annotations.	Acceleration derived measures (time and frequency domains, RMS, range, entropy, energy)	Yes, machine learning and leave one out validation technique validated in the lab and applied in free-living conditions and compared against patients' diaries. Use of videos in the lab for assessing symptoms severity using UPDRS	No	Yes, formal testing	






(Continued)

TABLE 1. Continued

Study (year), N, length of recording	WTCD and placement		Clinical feature/activity	Accurate detection of clinical feature: method of appraisal <sup>a</sup>	Measures	Criterion validity <sup>a</sup>	Discriminative validity <sup>a</sup>	Utility
	SENSE-PARK System	Activity AX3						
Ferreira et al (2015) <sup>23</sup> , 11 PD, 12 weeks			Gait, hypokinesia, dyskinesia, tremor, sleep	No/NA (feasibility study and usability)	NA	NA	No	Yes, formal testing
Hammerla et al (2015) <sup>24</sup> , 34 PD, 7			Sleeping, ON/OFF state, dyskinesia	Yes, in the lab (against video recordings) using machine learning and leave one out validation technique, in free-living conditions results are compared against patients' diaries. Model pretrained in free-living conditions did not give good results (laboratory data is a poor model for naturalistic behaviors)	Acceleration derived measures (magnitude, jerk, power spectral density, etc.)	No	No	Yes, formal testing but in subsequent work <sup>33</sup>
Horne et al (2015) <sup>20</sup> , 64 PD/38 OA, 10	Parkinson's KinetiGraph (PKG; Global Kinetics Corporation) 		Bradykinesia, dyskinesia, fluctuations	Yes, against measures of bradykinesia and dyskinesia (previous work see Griffiths [2012])	Fluctuation Score based on Interquartile Range of bradykinesia and dyskinesia scores.	Yes, against clinical scores derived measure	Yes	No
Prudon et al (2013) <sup>94</sup> , 106 PD/99 OA, 3 nights	Acti-watch, Camntech 		Leg movements during sleep	Yes, in patients with periodic leg movement (against electromyography), previous work	Periodic leg movements index	Yes, against disease severity	No	No
Louter et al (2015) <sup>25</sup> , 11 PD, 2 nights	Dynaport McRoberts 		Turning during sleep	Yes, against polysomnography in adults with obstructive sleep apnoea syndrome, previous work <sup>95</sup>	Acceleration derived measures (eg, mean) and axial movement measures (frequency, size, duration, speed)	Yes, against Acti-watch but in young healthy adults previous work <sup>95</sup>	Yes	Yes, no formal testing, previous work
Sringean et al (2015) <sup>26</sup> , 19 PD, 1 night	NIGHT-Recorder system 		Turning, standing	No, video and sleep diaries collected but validity not formally tested	Acceleration and gyroscope derived measures (duration of sleep, axial movements, velocity, etc.)	Yes, against clinical scores (UPDRS axial score, item #28, etc.)	Yes	Yes, no formal testing, no adverse events reported

(Continued)




TABLE 1. Continued

		Accurate detection of clinical feature: method of appraisal <sup>a</sup>		Clinical feature/activity	Measures		Criterion validity <sup>a</sup>	Discriminative validity <sup>a</sup>	Utility
Study (year), N, length of recording									
<i>Falls and falls risk</i> Weiss et al (2013) <sup>35</sup> , 71 OA, 3	 Dynaport McRoberts	No	Walking (at least 60 seconds)	Number of walking bouts, walking duration, total number of steps, median number of steps per bout, bout duration, cadence, step and stride regularity, frequency domain measures (harmonic ratio, amplitude, slope and width of dominant frequency), step duration, step symmetry, acceleration range, etc.	Yes, against clinical scores of fall risk and laboratory based measures	Yes	No		
Weiss et al (2014) <sup>36</sup> , 107 PD, 3	 Dynaport McRoberts	No	Walking (at least 60 seconds)	Number of walking bouts, % of activity duration, total number of steps, median number of steps per bout, bout duration, cadence, stride regularity, frequency domain measures (harmonic ratio, amplitude, and width of dominant frequency), etc.	Yes, against clinical scores of fall risk	Yes	Yes, no formal testing, data loss reported		
Brodie et al (2015) <sup>40</sup> , 18 EF, 58 (average)	Senior Mobility Monitor (SMM, Philips) 	No	Walking (at least 3 or 8 steps)	Steps per day, walking bouts per day, steps per bout, cadence, distribution of bout length	No	Yes	No		
Hjorth et al (2015) <sup>41</sup> , 48 PD, 7	activPAL 	Yes, but not formal in PD. Previous work in OA against other accelerometer <sup>95</sup> and video recordings	Sedentary behavior/standing/walking	Volume (eg, total number of sedentary/standing/walking bouts), pattern ( $\alpha$ ), variability of	Yes, against clinical scores	Yes	No		

(Continued)








TABLE 1. Continued

Study (year), N, length of recording	WTCD and placement	Clinical feature/activity	Accurate detection of clinical feature: method of appraisal <sup>a</sup>	Measures	Criterion validity <sup>a</sup>	Discriminative validity <sup>a</sup>	Utility
MacTier et al (2015) <sup>39</sup> , 111 PD, 7		Walking	in people with rheumatoid arthritis during simulation of ADL in the laboratory <sup>97</sup> Yes, but not formal in PD. Previous work in OA against other accelerometers <sup>96</sup> and video recordings in people with rheumatoid arthritis during simulation of ADL in the laboratory <sup>97</sup>	sedentary bouts, and number of strides per walking bout. Volume (eg, total number of walking bouts), pattern ( $\alpha$ ), variability of bouts, accumulation of stepping bouts	No	Yes	No
Rispens et al (2015) <sup>38</sup> , 113 OA, 14		Walking (at least 10 seconds)	Yes, previous work in OA <sup>98</sup> for walking volume parameters against videos, no for gait characteristics	Acceleration-based outcomes: gait speed, speed variability, stride time, stride regularity, stride time variability, stride frequency, frequency domain measures (harmonic ratio, amplitude, slope, and width of dominant frequency), etc.	Yes, measures against self-reported fall history	No	No
van Schooten et al (2015) <sup>37</sup> , 169 OA, 8		Walking (at least 10 seconds), sitting, lying, and standing	Yes, previous work in OA <sup>98</sup> for walking volume parameters against videos, no for gait characteristics	Total duration of walking, sitting, standing, and lying per day, number of strides, number of walking bouts, duration of bouts, number of transitions. Gait characteristics: gait speed, stride frequency, stride length frequency domain measures (harmonic ratio, power at dominant frequency), etc.	Yes, against falls history	Yes	No

(Continued)


TABLE 1. Continued

Study (year), N, length of recording	WTCD and placement	Clinical feature/activity	Accurate detection of clinical feature: method of appraisal <sup>a</sup>	Measures	Criterion validity <sup>a</sup>	Discriminative validity <sup>a</sup>	Utility
Kangas et al (2015) <sup>32</sup> , 16 OA, 5-155	CareTech Ab 	Falls <sup>c</sup>	Yes, fall event against care personnel's reports and in previous work in OA during simulation of fall events in controlled conditions <sup>99</sup> in OA	Fall event with alarm generation	No	No	Yes, based on alarm accuracy
<i>Freezing of gait (FOG)</i> Moore et al (2013) <sup>43</sup> , 25 PD, NA	Xsens MTx 	Turning/ walking (TUG) <sup>c</sup>	Yes, in the laboratory for FOG event against video recordings	FOG event through acceleration derived frequency measures (power spectrum, etc.).	No	No	No
Tripoliti et al (2013) <sup>44</sup> , 11 PD/5 OA, NA	Body Sensor AGYRO, AGYRO links, ANCO S.A. 	Walking, FOG detection <sup>c</sup>	Yes, against video recordings and visual inspection during structured test (opening door/straight 10-minute walking) sing different classification algorithms and cross-validations	FOG detection through entropy of WTCD signal	No	No	No
Weiss et al (2015) <sup>45</sup> , 72 PD, 3	Dynaport McRoberts 	Walking (at least 60 seconds)	No	Number of walking bouts, % of activity duration, total number of steps, median number of steps per bout, bout duration, cadence, stride regularity, frequency domain measures (harmonic ratio, width of dominant frequency), etc.	Yes, against clinical scores (FOG questionnaire)	Yes	No
<i>Gait</i> Cancela et al (2011) <sup>58</sup> , 10 PD, 1 (not clear)	ALA-6g (PERFORM) 	Walking (on vs off medication)	Yes, only for step frequency during 10-minute scripted protocol against visual examination	Step frequency, stride length and speed, entropy, arm swing	No	Yes, only for entropy in previous work <sup>100</sup>	No

(Continued)





























TABLE 1. Continued

		Accurate detection of clinical feature: method of appraisal <sup>a</sup>		Measures		Criterion validity <sup>a</sup>		Discriminative validity <sup>a</sup>		Utility	
Study (year), N, length of recording	Clinical feature/activity										
Weiss et al (2011) <sup>57</sup> , 22 PD/17 OA (1 PD/1 CL at home), 3	Walking (during scripted test in the lab and during simulation of ADL and free-living)	No		Acceleration derived measures (time and frequency domains): stride time, stride time variability, amplitude, width, slope of dominant frequency, etc.		Yes, against clinical scores		Yes		No	
		Mobis									
Cancela et al (2014) <sup>59</sup> , 11 PD, 5-7 (8 hours per day)	Walking	Yes, only for step frequency, previous work (see Cancela [2011])		Step frequency, step velocity, stride length, entropy		No		Yes, only for entropy in previous work <sup>100</sup>		Yes, formal testing and also assessed in separate study <sup>6</sup>	
		ALA-6g (PERFORM)									
Herman et al (2014) <sup>61</sup> , 110 PD, 3	Walking (at least 60 seconds)	No		Total number of activity bouts, total % of activity duration, total number of steps, mean activity bout duration, median number of steps per bout, cadence, stride regularity, amplitude of dominant frequency, width of dominant frequency, stride regularity, harmonic ratio, Phase Coordination Index		Yes, previous work		Yes, previous work		No.	
		Dynaport McRoberts									
Weiss et al (2015) <sup>60</sup> , 107 PD, 3	Walking (at least 60 seconds)	No		Total % of activity duration, total number of steps, cadence, amplitude of dominant frequency, stride regularity, harmonic ratio, Phase Coordination Index		Yes, previous work		Yes, previous work		Yes, no formal testing, data loss reported	
		Dynaport McRoberts									













(Continued)

TABLE 1. Continued

								
Study (year), N, length of recording	WTCD and placement	Clinical feature/activity	Accurate detection of clinical feature: method of appraisal <sup>a</sup>	Measures	Criterion validity <sup>a</sup>	Discriminative validity <sup>a</sup>	Utility	
Del Din et al (2016) <sup>49</sup> , 47 PD/50 OA, 7	Activity AX3 	Walking (at least 3 steps)	No	14 gait characteristics: mean step time, stance time, swing time, step length, step velocity, step time variability, stance time variability, swing time variability, step length variability, step velocity variability, step time asymmetry, stance time asymmetry, swing time asymmetry, step length asymmetry	Yes, gait characteristics validated against laboratory reference (previous work <sup>53</sup> )	Yes	No	
<i>Timed-up-and-go (TUG)</i>								
Zampieri et al (2011) <sup>62</sup> , 6 PD/8 OA, 1	Physilog   	Walking/turning/postural transitions <sup>c</sup>	Yes, in previous work <sup>101</sup>	Cadence, stride velocity, stride length, peak arm velocity, turning velocity	No	Yes	No	
Smith et al (2016) <sup>63</sup> , 12 OA, 5	SHIMMER 	Walking/turning <sup>c</sup>	No	Time to complete test, cadence, gait characteristics (step time, stride time, stride length, stride velocity, etc.), turning magnitude, etc.	No	No	No	
<i>Turning</i>								
El-Gohary et al (2013) <sup>65</sup> , 12 PD/18 OA, 7 <sup>b</sup>	Opal(ADPM)                    							

(Continued)



TABLE 1. Continued

							
Study (year), N, length of recording		Clinical feature/activity	Accurate detection of clinical feature: method of appraisal <sup>a</sup>	Measures	Criterion validity <sup>a</sup>	Discriminative validity <sup>a</sup>	Utility
<i>Ambulatory activity and sedentary behavior</i>							
Chastin et al (2007) <sup>71</sup> , 17 PD/17 OA, 7	activPAL 	Sedentary behavior	Yes, but not formal in PD. Previous work in OA against other accelerometer <sup>96</sup> and video recordings in people with rheumatoid arthritis during simulation of ADL in the laboratory <sup>97</sup>	Volume of sedentary bouts, pattern ( $\alpha$ ), pattern of accumulation of bouts (GINI index)	No	Yes	No
Dontje et al (2013) <sup>70</sup> , 467 PD, 14	TracmorD, Philips/ --  or --  or 	Physical activity/sedentary behavior	Yes, against doubly labeled water technique (correlation) in adults but not in PD <sup>102</sup>	Energy expenditure, time spent in activities, distribution of activities, etc.	Yes	No	No
Benka Wallen et al (2015) <sup>103</sup> , 95 PD, 7	ActiGraph GT3X+  --	Physical activity/sedentary behavior/steps (60-second epochs)	Yes, in young adults under controlled conditions by visual observation but not in PD <sup>104</sup>	Volume (magnitude vector of acceleration) and time spent in physical activities, steps per day, etc.	No	No	No
Lim et al (2010) <sup>74</sup> , 153 PD, 1	Vitaport3, TEMEC Instruments BV    	Sitting, standing, walking	Yes in PD against video (under controlled conditions), previous work <sup>105</sup>	% of time spent on dynamic, static, sitting, standing or walking activities, number of walking bouts > 5 seconds and > 10 seconds	No	No	No
Cavanaugh et al (2012) <sup>72</sup> , 33 PD, 7	StepWatch 3 Step Activity Monitor (SAM) 	Walking (average every 60 seconds)	Yes, for stride count in PD against instrumented walkway in the lab, previous work <sup>106</sup>	Total number of steps, maximum output for steps, number of minutes with > 100 steps, number and duration of walking bouts, peak activity index, % of day spent inactive	No	No	Yes, not formal testing, reasons for data loss and attrition in sensor acceptability after 1 year with decrease in participant use reported
Rochester et al (2012) <sup>68</sup> , 17 PD, 7	activPAL 	Walking	Yes, but not formal in PD. Previous work in OA against other accelerometer <sup>96</sup> and video recordings	Volume of walking bouts, pattern of accumulation of bouts (GINI index) and diversity of bouts,	Yes	No	No

(Continued)

(Continued)

TABLE 1. Continued


Study (year), N, length of recording	WTCD and placement		Clinical feature/activity	Accurate detection of clinical feature: method of appraisal <sup>a</sup>	Measures	Criterion validity <sup>a</sup>	Discriminative validity <sup>a</sup>	Utility
Lord et al (2013) <sup>66</sup> , 89 PD/97 OA, 7	activPAL		Walking	in people with rheumatoid arthritis during simulation of ADL in the laboratory <sup>97</sup> Yes, but not formal in PD. Previous work in OA against other accelerometers <sup>96</sup> and video recordings in people with rheumatoid arthritis during simulation of ADL in the laboratory <sup>97</sup>	distribution and variability of bouts (S <sub>2</sub> ) Volume of walking bouts, pattern (α), time spent walking in short-medium or long bouts, frequency and variability of bouts (S <sub>2</sub> )	Yes	Yes	No
Cavanaugh et al (2015) <sup>73</sup> , 17 PD, 7	StepWatch 3 Step Activity Monitor (SAM)		Walking (average every 60 seconds)	Yes, for stride count in PD against instrumented walkway in the lab, previous work (see Cavanaugh [2012])	Mean daily steps, maximum output for steps, moderate intensity minutes (number of minutes with > 100 steps)	Yes	No	Yes, not formal testing, reasons for data loss and attrition in sensor acceptability after 2 years with decrease in participant use reported

Number and position of WTCD used in each study is detailed in column two using a color code (blue = chest, violet = wrist, black = pocket, green = thigh, yellow = shank, orange = ankle, gray = foot, red = lower back).

<sup>a</sup>Clinical feature or activity detected or measures has been classified using three types of validity: (1) accurate detection of clinical feature or method of appraisal: the ability of WTCD algorithms to accurately detect a clinical feature or activity that is comparable to detection by another means—in the study cited or previous studies (eg, self-report, EMG); (2) criterion validity: the association between WTCD-derived outcomes and measures such as clinical scales; and (3) discriminative validity: the ability of WTCD-derived outcomes to discriminate between groups. Formal testing of utility (feasibility or compliance intentionally tested and reported) of WTCD is also reported. ADL, activities of daily living; AIMS, Abnormal Involuntary Movement Score; Alpha,  $\alpha$ ; lab, laboratory; length of recording, number of weeks/days per minute of recording; MBRS, Modified Bradykinesia Rating Scale; min, minutes; N, number of participants; OA, older adults; PD, Parkinson's disease; RMS, root mean square; UPDRS, Unified Parkinson's Disease Rating Scale; %, percentage.

<sup>b</sup>Night excluded.

<sup>c</sup>Scripted protocol or supervised conditions used.




**FIG. 2.** Examples of linear and nonlinear approaches to activity data analysis: volume and pattern metrics for 2 patients (patients 1 and 2; published with permission).<sup>68</sup> (A1 and A2) Patterns of activity indicating bouts of sedentary, standing, and walking at different stepping rates (cadences). (B1 and B2) Volume metrics: Total walking time for the 2 patients is equal but made up of walking bouts at different cadences. (C) Pattern metrics: (i) and (ii) distribution of walking bouts for these 2 patients with equal mean ( $M$ ) and different dispersion ( $S_2$ ). (C) (iii) Accumulation pattern of walking time for patients 1 and 2; patient 2 tends to accumulate walking time with predominantly longer periods.

professionals use WTCD? Table 1, which forms the basis of this section, provides an overview of the detection accuracy, validity, and utility of some WTCD. Our main inclusion criterion was that WTCD had been applied to free-living monitoring under either totally unsupervised or scripted protocol conditions, with an exception made for studies in which tests are conducted in formal settings to optimize validation, such as the detection of FOG. We report criterion validity from studies that examine the association between WTCD-derived outcomes and other measures such as clinical scales. We also report studies that test discriminative validity, which we define as the ability of WTCD-derived outcomes to discern groups or phenotypes. The list is by no means exhaustive but provides a current overview and highlights the vast interest in the area. We do not review static postural control despite its obvious relevance to PD<sup>14,15</sup> because studies are laboratory or clinic based; however, facets of postural control (eg, dynamic, turning) are considered.

### Motor Symptoms, Medication Response, and Sleep

Continuous monitoring has a lot to offer over snapshot clinical assessments that may not reveal the true extent of symptom burden. Earlier use of WTCD for motor symptom measurement focused on the evaluation of a single symptom to detect hypokinesia, dyskinesia, tremor, bradykinesia, and akinesia derived on/off medication status.<sup>16,17</sup> This has evolved to the assessment of multiple motor symptoms using either a single<sup>18-20</sup> or multiple-sensor systems.<sup>17,21-24</sup> To date,

preliminary results are promising. Overall, motor symptom measurement using WTCD is accurate and comparable with more established methods with some aspects of validity tested. Criterion validity is established for most motor symptoms (tremor, bradykinesia, dyskinesia), showing moderate to high correlations overall ( $R > .65$ ) with standard clinical scales (eg, UPDRS, Abnormal Involuntary Movement Score, Modified Bradykinesia Rating Scale, etc.; see Table 1 for references). Measures of bradykinesia also show high specificity (88%) and sensitivity (95%) when compared with standardized tests (eg, the Dot Slide test).<sup>18</sup> Studies that test discriminative validity are not as advanced apart from the work by Horne and colleagues, which discerns motor symptom fluctuations in early stages of PD.<sup>20</sup> Single sensors are sufficiently robust for application, although there are questions over utility aspects for some systems that require technical mastery and are demanding on the user (see the Utility section). Although there have been a number of key developments in this area with motor-symptom monitoring assessed at home, the test protocols are still largely controlled and scripted as highlighted in Table 1. True passive monitoring without patient input is as yet an area to be developed, but remains the area of greatest interest because it will give the most ecologically valid picture of motor symptom burden and therapeutic efficacy. The assessment of sleep also shows promise. WTCD-derived outcomes for sleep-discriminate PD from older adults (OA)<sup>25,26</sup> for macro outcomes (eg, number and size of movements) with people with PD also shows increased episodes of nocturia, fewer turns during sleep, and greater arm movements.



**FIG. 3.** Challenges or limitations of free-living measurement using examples from gait in free-living collected with a single accelerometer-based wearable technology and connected devices. Data (unpublished) from the Incidence of Cognitive Impairment in Cohorts With Longitudinal Evaluation-GAIT (ICICLE-GAIT) study.<sup>107</sup> Panel 1: Definition of feature of interest (eg, walking). (A) Impact of “selected” definition of walking on data processing: different threshold of walking bout length and (ghost) maximum resting period (MRP) between consecutive walking bouts can be utilized. Examples: (i) use of walking bout threshold of 60 seconds and no MRP (MRP = 0 seconds; only bouts longer than 60 seconds will be considered); (ii) use of walking bout threshold of 3 steps and no MRP (MRP = 0 seconds); (iii) use of walking bout threshold of 3 steps and MRP = 5 seconds. (B) Impact of choice in (A) on macro outcomes (eg, number of bouts considered, total number of steps reported for people with Parkinson’s disease [PD] and controls [CL]). For example, using definition (i) only a small percentage of all the walking bouts will be considered (bouts > 60 seconds only), and therefore fewer steps will be reported if compared with results of using definition (ii). (C) Impact of choice in (A) on micro gait characteristics (eg, reported step velocity may vary across studies as a result of choice of definition i, ii, or iii). Panel 2: Influence of free-living protocol on data. Walking speed changes with respect to the environment, task, and disease severity that influences the accelerometer raw signal (D) impacting on algorithm performance and evaluation of outcomes (E).

## Falls and Falls Risk

Accurate detection of falls and falls risk (ideally before the first-ever fall) would greatly inform clinical management and therapeutic development, and WTCD has a role to play. Real-world detection of falls, however, is technically challenging. A plethora of algorithms, devices, and device locations (chest, waist, or wrist<sup>27-31</sup> have been tested to improve the accuracy of fall detection; however, studies are almost completely limited to controlled settings and conducted on young healthy adults. Kangas and colleagues provides a rare example of using WTCD for falls detection in the real-world, where falls were measured in institutionalized OA and verified by an observer.<sup>32</sup> Fall detection sensitivity was 80%, with a falls alarm rate per hour of 0.025, denoting 1 false alarm over 40 hours of recording. This points to high

accuracy, although the testing environment was far removed from free living, and generalizability is therefore weak. Application in PD remains an area of unmet need. An alternative approach is to predict falls risk using WTCD that, in contrast to falls detection, is a more advanced field for both OA and PD. Moreover, addressing a falls prevention approach could be argued to have greater clinical relevance.<sup>33,34</sup> Studies have compared groups with and without falls in PD using free-living monitoring for 3 to 7 days. Falls risk factors derived from gait during free-living walking bouts<sup>33,34</sup> were superior to laboratory-based gait speed and fall history to discriminate fallers from nonfallers.<sup>35-38</sup> Discriminative validity has been established for both macro and micro characteristics of gait and sedentary behavior (Fig. 1A-B), which are associated with type of PD fallers<sup>39</sup> and fall history (fallers vs



**TABLE 2.** Practical solutions and broad recommendations for wearable technology and connected devices (WTCD)–related research challenges

Recommendation	Practical solutions
Adopt standardized definition of activity/clinical feature.	<ul style="list-style-type: none"> <li>Justify definition of activity/clinical feature with respect to earlier work and clinical expertise.</li> <li>Adopt interdisciplinary collaboration for optimal process, choice of equipment, protocol, data processing, and outcomes adhering to research question(s).</li> </ul>
Select equipment depending on research/clinical question; evaluate trade-off between information needed and equipment available.	<ul style="list-style-type: none"> <li>Consider optimal technical specifications (eg, sampling frequency, type of data collected; battery life) for outcome measures.</li> <li>Use WTCD with established utility, acceptability, and cost-effectiveness, otherwise plan to include tests of utility and acceptability as part of the study.</li> <li>Ensure transparency of all aspects of technology used (specifications, data collection, data preprocessing).</li> </ul>
Use standardized protocols and validation procedures for algorithms for comparability and reproducibility across studies (eg, accurate detection of activity/clinical feature, criterion and discriminative validity).	<ul style="list-style-type: none"> <li>Justify use of standardized protocol and methods to define activities/clinical features.</li> <li>Use algorithms previously validated for the current application or provide validation results for novel algorithms.</li> <li>Use appropriate gold standards (eg, video recording) to validate outcomes/metrics in free-living conditions, not limiting validation to scripted protocols or controlled conditions.</li> <li>Account for influence of context and disease severity on algorithm performance.</li> <li>If proprietary software is used, ensure transparency of manufacturer algorithms or report published validated algorithm.</li> </ul>
Achieve consensus for summary outcomes for comparability across studies.	<ul style="list-style-type: none"> <li>Use WTCD-based outcomes validated in free-living or provide validation results in the current study using semistructured activities.</li> <li>Describe dependence (if any) of chosen summary outcomes and on chosen data processing/algorithm.</li> </ul>

nonfallers) in OA<sup>38,40</sup> and PD,<sup>41</sup> respectively. Micro features may offer more than macro features<sup>36,37</sup> and contribute substantially to predicting falls both in fallers and nonfallers.<sup>37,38</sup> Further refinement of algorithm and system development is required to move the field forward.

### Freezing of Gait

Gait disturbances such as FOG are notoriously difficult to replicate in a controlled environment because of its spontaneous nature and the nonspecific and poorly understood triggers that provoke it.<sup>3</sup> Clinical scales such as the UPDRS and new FOG (NFOG)<sup>42</sup> are subjective and therefore limited. Despite the obvious need, free-living monitoring of FOG in PD has not been achieved. Detection of FOG episodes has been tested in controlled and structured conditions where FOG is provoked during the off condition using either timed-up-and-go<sup>43</sup> or walking tasks.<sup>44</sup> Studies show high sensitivity (range 84.3% to 86.2%) and moderate to high specificity (range 66.7% to 98.74%) for detection of FOG and moderate agreement with clinical measures.<sup>43,44</sup> These results provide a critical step from which validation can be extended to free living. An alternative approach is to identify potential predictors of FOG to understand the mechanisms and target therapeutic developments. A recent study comparing freezers versus nonfreezers found frequency-based gait characteristics collected during 3 days of free living discriminated freezers. Gait characteristics were also moderately correlated with clinical measures of FOG.<sup>45</sup> Further work is needed before free-living

monitoring can be used for FOG detection or indeed for understanding the characteristics of FOG, but initial results are promising.

### Gait

Measurement of gait per se (micro characteristics; Fig. 1E-F) is also of interest to the clinician to evaluate the efficacy of clinical management (because of dopa resistance) as well as for its potential for use of discrete gait characteristics as diagnostic, prognostic, and progression markers.<sup>46-48</sup> Gait assessment during free-living assessment also captures ongoing environmental and cognitive challenges that impair gait performance. Assessment in this context has greater ecological validity and gives a true picture of the burden of disease.<sup>3,7,49</sup> Algorithms have been validated to detect discrete gait characteristics in the laboratory and also in proxy validation studies.<sup>50-55</sup> Results showed good agreement with trusted gold standard reference (eg, GaitRite or optical motion capture systems) for the majority of gait characteristics with potential advantages for asymmetry and variability measures. Apart from Del Din and colleagues,<sup>49</sup> the few studies that have examined gait in free-living conditions quantify few gait characteristics.<sup>56-61</sup> Discriminative validity has been tested and has been shown to discriminate between PD and OA,<sup>49,57</sup> phenotypes of PD,<sup>61</sup> and PD with higher or lower cognitive functions.<sup>60</sup> Aside from studies exploring falls and FOG risk highlighted previously,<sup>57</sup> only 1 study has investigated the effect of environment on gait. Free-living gait characteristics showed better discriminative validity than those

collected in the laboratory, especially for medium to long bouts.<sup>49</sup> Although initial work is promising, future work is required to confidently realize the continuous monitoring of gait. There are also some fundamental challenges to the field (outlined in the next sections).

### Measures of Functional Mobility

Tests of functional mobility such as turning and Timed Up and Go<sup>62-64</sup> measure combined movements that invariably incorporate postural transitions. Detection of movements during functional mobility tasks appears accurate,<sup>62,63,65</sup> and validity (criterion and discriminative) has been established by a limited number of studies.<sup>62,65</sup> Mean turn velocity, slower walking and turning, shorter steps, and lower cadence distinguished PD from controls<sup>62,64</sup> and also showed greater sensitivity to dysfunction than clinical rating scales.<sup>64,65</sup> Of interest, free-living assessment appears to discriminate pathology better than testing in the laboratory<sup>54</sup> (Fig. 1G). The measurement of functional mobility tasks can therefore be undertaken with a degree of confidence during a standardized test at home, although further work is required to replicate these findings.

### Ambulatory Activity and Sedentary Behavior

One of the earliest applications of WTCD aimed to quantify physical activity (eg, ambulatory activity) amid rising concerns of the negative effects of sedentary behavior on well-being. This is particularly relevant for people with PD because of the beneficial health benefits activity confers and its role in mitigating secondary deficit. Ambulatory activity provides a picture of the true burden of disease and therapeutic efficacy.<sup>66</sup> Proxy measures such as activity logs and diaries are unreliable and lack responsiveness when compared with continuous WTCD monitoring.<sup>67</sup> Macro outcomes can be derived from physical activity such as intensity of movement (energy expenditure), temporal periods (bouts) of ambulatory activity (eg, bouts of walking), and sedentary behaviors that are quantified (Fig. 1A-B).<sup>66,68-70</sup> The field has advanced further with the application of nonlinear approaches to data analysis that in some instances are more sensitive than measures of central tendency (Table 1, Fig. 2), such as pattern (alpha [ $\alpha$ ]) rather than volume of sedentary behavior showing discriminative properties.<sup>71</sup> Ambulatory activity differentiates disease stage<sup>66</sup> and progression<sup>72,73</sup> and shows increased sensitivity to intervention.<sup>68,74</sup> Rochester and colleagues<sup>68</sup> demonstrated the advantages of WTCD versus clinical measures when examining the impact of deep brain stimulation (DBS) on ambulatory activity. Although standard clinical measure for gait speed (4-meter test), levels of activity (Nottingham Extended Activities of

Daily Living Index), and disease progression (Hoehn and Yahr) failed to show the positive effects of DBS on the outcomes, WTCD-based measures demonstrated significantly improved patterns of daily activity. The use of WTCD to measure ambulatory activity and sedentary behavior is the most advanced of all the fields discussed in this section and the most widely adopted. Nonetheless, there are still questions over its application, driven by lack of common definitions of ambulatory activity, validation procedures, and structured protocols in controlled settings for validation of algorithms.<sup>6</sup> These will be considered in the next sections.

### Utility and Feasibility of WTCD: How Acceptable Are They?

Most studies do not intentionally test the feasibility and utility of WTCD but instead draw on secondary data such as informal comments from patients, reports of adverse events, data loss, or attrition in sensor use during the study period. Importantly, there are no overwhelmingly negative reports, suggesting that WTCD are broadly accepted. Although a few studies have intentionally tested utility (which we describe as formal testing in Table 1), some focused efforts have been made. Utility has been tested for wearable systems comprising interactive<sup>75</sup> or multiple sensors,<sup>17,22,23,76</sup> using both nonstandardized and standardized questionnaires and rating scales<sup>23</sup> (eg, the poststudy usability questionnaire), comfort<sup>75,76</sup> (eg, comfort rating scale), and wearability or exertion<sup>76</sup> (eg, Borg CR-10 Scale, Rapid Entire Body Assessment). Overall, the response has been positive, with WTCD generally well tolerated, comfortable, and easy to use. Compliance is high, although in some cases results were influenced by sociocultural aspects that may have positively biased results.<sup>23</sup>

In summary, to date there is no fully validated WTCD system for continuous monitoring of patient clinical features. Overall, studies are small, there is no consistent reporting of outcome measures, protocols differ, and devices differ along with device placement. Comparison to a gold standard is difficult, and knowledge on patient acceptability is limited. A clear process for validation including replication in external data sets is essential with appropriate reporting according to a standard. However, the WTDC community is aware that this is an important and emerging area of research with potential for high clinical uptake, and collaborative efforts are underway to redress these issues (see reviews<sup>7-9</sup>). Challenges to implementation are due at least in part to broader technological and practical concerns that are common to all WTCD and influence their state of readiness, irrespective of application and use. Until these fundamental issues are redressed, robust use of WTCD will be compromised.

The next section highlights some of these broad concerns and discusses approaches to advance the field.

## Challenges to Clinical Adoption

We address the following 3 key areas fundamental to the use of WTCD that apply to all areas of measurement: (1) clear definitions of the clinical feature of interest, (2) validation of real-world data and WTCD technical challenges, and (3) consensus on outcomes. We illustrate these using examples from our own experience in gait and activity and that of others (Fig. 3). Finally, we summarize the challenges with recommendations for future work and practical suggestions to inform the interested user (Table 2).

### Defining the Clinical Feature

Although on the face of it this seems simple, there are many examples where unclear definitions have led to inconsistencies in outcomes and confusion when comparing studies. A good example relates to ambulatory activity, from which macro- (eg, walking bouts) and micro-level gait outcomes are derived that underpin many different clinical and research questions (Fig. 1). This stems from a basic definition of what constitutes a walking bout. In some studies, only purposeful bouts of walking are considered (with a cut-off threshold > 60 seconds) because regular steady state is more likely to be achieved, thus avoiding potential errors in misclassification from short bouts. However, this is problematic because adults perform almost 90% of walking bouts in less than 60 seconds,<sup>40,49,77</sup> resulting in significant data loss and potentially missing the most relevant data (such as change in variability of walking pattern). Another approach is to include all bouts of walking,<sup>49</sup> which is arguably more relevant in patient populations. However, this is not a complete solution because disagreement also exists regarding the number of steps required for a bout, which may vary, ranging from >3 steps to >10 steps. As a consequence, comparison across studies is impossible where difference in step counts range from 2000 to 10,000 steps.<sup>66,68,72,73</sup> The situation is further complicated by the use of ghost (unknown to the end user and hard-wired into WTCD) thresholds used by the manufacturer to define consecutive bouts of walking that have a major impact on macro outcomes<sup>78</sup> (eg, total number and pattern of walking bouts; Fig. 3[1]). This uneven approach significantly impacts on both macro and micro outcomes, and therefore consensus as to a clear definition of walking is urgently required.<sup>6,78</sup> Attempts are underway to improve definitions that will greatly help (Chastin et al.: ALPHABET: Development of A Physical Behaviour Taxonomy with an international open consensus; <https://osf.io/2wuv9/>).<sup>1</sup>

## Algorithm Development, Validation, and Technical Challenges: Influence of Context and Protocol

Establishing a gold standard to test algorithm validity for the range of features highlighted in this review during continuous uncontrolled monitoring in a free-living environment is a major challenge without obvious solutions. Real life is unpredictable and unstructured. For example, context (environment and task) affects walking speed and direction, which has implications for accuracy of algorithms used to detect steps and phases of the gait cycle from which gait characteristics are determined (Fig. 3). Studies often adopt a number of different testing protocols and various sensor configurations (type and location [upper or lower body], Table 1), which also impacts the signal waveform, influencing the accuracy of the algorithm used to extract micro outcomes and other types of information (features, outcomes). Moreover, algorithms are usually validated using healthy control data and adopted for analyzing other groups' data (ie, PD) without considering that speed (fast or slow), pathology itself, or disease stage may impact the raw signal (Fig. 3[2]) and therefore influence algorithm performance. In addition, other technical considerations need to be taken into account. Many commercial devices adopt black box designs with unvalidated firmware or software<sup>79</sup> that accounts for at least some of the significant disagreements in reported results.<sup>80,81</sup> Other uncertainties because of externally induced motion (eg, cars, lifts) also impact the accuracy to detect features of interest.<sup>81</sup> Static and dynamic recalibration of WTCD to account for possible axis misalignment or sensor alterations because of damage (device dropped, contact with water, etc.) is also advised<sup>82</sup> but rarely undertaken because procedures are complicated and expensive. Further sources of variability are also introduced through changes in external factors such as weather, mood, or medication, influencing analysis of the signal. Collectively, these result in errors and decreased confidence in outcomes and conformity to everyday use. Algorithm development will ultimately refine extraction, and a joint approach such as use of secondary data sources will aid interpretation, for example, data from patients' diaries, testimony from caregivers, and use of clinical records.<sup>83</sup> All of these potential sources of error should be considered, and some suggestions are provided in Table 2.

### Determining Optimal Outcome Measures

Table 1 shows the vast range of outcomes reported. Standardized measurement is urgently needed with a clear rationale for selection of outcomes from which clinimetric testing will allow a refined battery of measures to emerge to encourage harmonization across

studies. Examples of measurement frameworks have been described,<sup>46,49</sup> including our micro- and macro-level structures used throughout this article.<sup>47</sup> Others<sup>37,38,45,57,61</sup> besides volume outcomes (eg, total number of walking bouts, etc.) defined as *quantity* metrics, use novel frequency-based outcomes to characterize gait symmetry, variability, and stability (eg, harmonic ratio, amplitude of dominant frequency, dynamic stability, etc.) defined broadly as *quality* metrics. These novel quality measures, although very promising for discriminative validity, may be difficult to interpret in clinical practice.

## Free-Living Monitoring in PD: Where to Next?

Modern devices incorporate a range of inertial sensors such as accelerometers, gyroscopes, and magnetometers with Bluetooth connectivity that constitute cutting-edge WTCD. Although use is currently limited to controlled settings, improvements in battery technology will improve the accuracy of measurement, addressing some of the challenges highlighted earlier. Moreover, novel methods for advanced data processing are being developed to reduce computational load with advanced computational processing carried out remotely via smartphone or in the cloud, extending the application of WTCD.<sup>84</sup> Studies have also investigated the use of smart phones (and audio devices) that regularly come with the necessary hardware to quantify symptoms, movement, or gait.<sup>85</sup> These devices capture, analyse, and relay information via cellular or other wireless networks and also provide a more comprehensive assessment such as the addition of a microphone for use with speech analysis algorithms in PD diagnosis<sup>86,87</sup> and visual displays to facilitate applications (apps) for the study of cognition.<sup>88</sup> Rigorous device testing, however, is needed to ensure confidence in their application.

Long-term monitoring via a smart phone facilitates network interconnectivity and integration to the Internet of Things<sup>5</sup> through delayed or real-time uploading of data to cloud computing infrastructures. Data can be relayed to the patient (biofeedback) via unobtrusive displays and haptic and audible cues. Data are stored and sent to clinicians for tracking disease progression, optimizing disease management and providing more clinically informed feedback to the patient. Data storage and data access on this scale constitutes big data analytics. Developments in this field can expand the assessment to capture the lived experience or life space of PD, capturing the extent to which people travel and their patterns of movement within the community.<sup>89</sup> This is exemplified by a recent collaborative project between the Michael J. Fox Foundation and Apple utilizing their projects, FoxInsight (The Michael J. Fox

Foundation for Parkinson's Research, <https://foxinsight.michaeljfox.org/>) and the Apple ResearchKit (Apple Inc., <http://www.apple.com/uk/researchkit/>; the Parkinson mPower [<http://parkinsonmpower.org/>] app available via iTunes), respectively.

The collection of data on the scale and in a free-living context raises new ethical challenges with respect to acquisition, analysis, and storage. Current ethical reviews may not be sufficient to identify modern issues.<sup>90</sup> Technology and terminology have evolved faster than legal and ethical systems, and unforeseen issues can emerge.<sup>91</sup> Informed, principled, and collaborative experimentation are therefore necessary to ensure privacy, confidentiality, and compliance with ethical principles.

## Conclusions and Recommendations

There is no doubting the possibilities and potential of real-world monitoring and assessment of clinical features for people with PD. It is conceivable to imagine a future where micro-level data are used to enhance diagnostics, measure efficacy of intervention, monitor disease progression, and predict the risk of disease, falls, and cognitive decline. Macro-level data, on the other hand, reflect the global burden of disease and the impact of therapy. Both sources of data provide insights into personalized treatment. As this special issue in the journal indicates, this is a rapidly developing field. However, much work remains before widespread clinical adoption is a reality. We highlight key recommendations and some practical solutions to move this field forward (Table 2). These challenges are likely to be met most effectively by adopting a multidisciplinary approach between key stakeholders such as clinicians, patients, engineers, computer scientists, and statisticians. ■

**Acknowledgments:** We thank Dr. Brook Galna for his support in editing Figure 1.

## References

1. Lowe SA, O'Leary G. Monitoring human health behaviour in one's living environment: a technological review. *Med Eng Phys* 2014;36(2):147-168.
2. Robles-Garcia V, Corral-Bergantinos Y, Espinosa N, et al. Spatio-temporal gait patterns during overt and covert evaluation in patients with Parkinson's Disease and healthy subjects: is there a Hawthorne effect? *J Appl Biomech* 2015;31(3):189-194.
3. Maetzler W, Rochester L. Body-worn sensors-the brave new world of clinical measurement? *Mov Disord* 2015;30(9):1203-1205.
4. Steins D, Dawes H, Esser P, Collett J. Wearable accelerometry-based technology capable of assessing functional activities in neurological populations in community settings: a systematic review. *J Neuroeng Rehabil* 2014;11:36.
5. Pasluosta C, Gassner H, Winkler J, Klucken J, Eskofier B. An emerging era in the management of Parkinson's disease: wearable technologies and the Internet of things. *IEEE J Biomed Health Inform* 2015;19(6):1873-1881.



6. Awais M, Mellone S, Chiari L. Physical activity classification meets daily life: Review on existing methodologies and open challenges. *37th Annual International Conference Proceedings of IEEE EMBS (EMBC)*. 2015;5050-5053. doi: 10.1109/EMBC.2015.7319526
7. Hobert MA, Maetzler W, Aminian K, Chiari L. Technical and clinical view on ambulatory assessment in Parkinson's disease. *Acta Neurol Scand* 2014;130(3):139-147.
8. Maetzler W, Domingos J, Srulijes K, Ferreira JJ, Bloem BR. Quantitative wearable sensors for objective assessment of Parkinson's disease. *Mov Disord* 2013;28(12):1628-1637.
9. Godinho C, Domingos J, Cunha G, et al. A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson's disease. *J Neuroeng Rehabil* 2016;13(1):24.
10. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord* 2008;23(15):2129-2170.
11. Ossig C, Antonini A, Buhmann C, et al. Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease. *J Neural Transm (Vienna)* 2016;123(1):57-64.
12. Papapetropoulos S, Mitsi G, Espay AJ. Digital health revolution: is it time for affordable remote monitoring for Parkinson's disease? *Front Neurol* 2015;6:34.
13. Godfrey A, Lara J, Del Din S, et al. iCap: instrumented assessment of physical capability. *Maturitas* 2015;82(1):116-122.
14. Schoneburg B, Mancini M, Horak F, Nutt JG. Framework for understanding balance dysfunction in Parkinson's disease. *Mov Disord* 2013;28(11):1474-1482.
15. Horak F, King L, Mancini M. Role of body-worn movement monitor technology for balance and gait rehabilitation. *Phys Ther* 2015;95(3):461-470.
16. Cancela J, Pansera M, Pastorino M, Pastor L, Arredondo MT. Automatic assessment of bradykinesia severity in patients with Parkinson's disease. Paper presented at: 7th International Conference on Wearable Micro and Nano Technologies for Personalized Health, Berlin (Germany), 2010.
17. Pastorino M, Cancela J, Arredondo MT, Pastor-Sanz L, Contardi S, Valzania F. Preliminary results of ON/OFF detection using an integrated system for Parkinson's disease monitoring. *Annual International Conference Proceedings of IEEE EMBS IEEE Engineering in Medicine and Biology Society Annual Conference* 2013:941-944.
18. Griffiths RI, Kotschet K, Arfon S, et al. Automated assessment of bradykinesia and dyskinesia in Parkinson's disease. *J Parkinsons Dis* 2012;2(1):47-55.
19. Mera TO, Heldman DA, Espay AJ, Payne M, Giuffrida JP. Feasibility of home-based automated Parkinson's disease motor assessment. *J Neurosci Methods* 2012;203(1):152-156.
20. Horne MK, McGregor S, Bergquist F. An objective fluctuation score for Parkinson's disease. *PLoS ONE* 2015;10(4):e0124522.
21. Das S, Amoedo B, De la Torre F, Hodgins J. Detecting Parkinson's symptoms in uncontrolled home environments: a multiple instance learning approach. *Annual International Conference Proceedings of IEEE EMBS IEEE Engineering in Medicine and Biology Society Annual Conference* 2012:3688-3691.
22. Tzallas AT, Tsipouras MG, Rigas G, et al. PERFORM: a system for monitoring, assessment and management of patients with Parkinson's disease. *Sensors (Basel, Switzerland)* 2014;14(11):21329-21357.
23. Ferreira JJ, Godinho C, Santos AT, et al. Quantitative home-based assessment of Parkinson's symptoms: the SENSE-PARK feasibility and usability study. *BMC Neurol* 2015;15:89.
24. Hammerla NY, Fisher JM, Andras P, Rochester L, Walker R, Plötz T. PD disease state assessment in naturalistic environments using deep learning. Paper presented at: Twenty-Ninth AAAI Conference on Artificial Intelligence; Austin, Texas (USA), 2015.
25. Louter M, Maetzler W, Prinzen J, et al. Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls. *J Neurol Neurosurg Psychiatry* 2015;86(1):32-37.
26. Sringean J, Taechalerpaisarn P, Thanawattano C, Bhidayasiri R. How well do Parkinson's disease patients turn in bed? Quantitative analysis of nocturnal hypokinesia using multisite wearable inertial sensors. *Parkinsonism Relat Disord* 2016;23:10-16.
27. Bourke AK, O'Donovan KJ, Nelson J, GM OL. Fall-detection through vertical velocity thresholding using a tri-axial accelerometer characterized using an optical motion-capture system. *Annual International Conference Proceedings of IEEE EMBS IEEE Engineering in Medicine and Biology Society Annual Conference* 2008:2832-2835.
28. Bourke AK, Torrent M, Parra X, Catala A, Nelson J. Fall algorithm development using kinematic parameters measured from simulated falls performed in a quasi-realistic environment using accelerometry. *Annual International Conference Proceedings of IEEE EMBS IEEE Engineering in Medicine and Biology Society Annual Conference* 2011:4449-4452.
29. Bourke AK, van de Ven P, Gamble M, et al. Assessment of waist-worn tri-axial accelerometer based fall-detection algorithms using continuous unsupervised activities. *Annual International Conference Proceedings of IEEE EMBS IEEE Engineering in Medicine and Biology Society Annual Conference* 2010:2782-2785.
30. Kangas M, Konttila A, Lindgren P, Winblad I, Jamsa T. Comparison of low-complexity fall detection algorithms for body attached accelerometers. *Gait Posture* 2008;28(2):285-291.
31. Kangas M, Konttila A, Winblad I, Jamsa T. Determination of simple thresholds for accelerometry-based parameters for fall detection. *Annual International Conference Proceedings of IEEE EMBS IEEE Engineering in Medicine and Biology Society Annual Conference* 2007:1367-1370.
32. Kangas M, Korpelainen R, Vikman I, Nyberg L, Jamsa T. Sensitivity and false alarm rate of a fall sensor in long-term fall detection in the elderly. *Gerontology* 2015;61(1):61-68.
33. Henderson EJ, Lord SR, Close JC, Lawrence AD, Whone A, Ben-Shlomo Y. The ReSPonD trial—rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen. *BMC Neurol* 2013;13:188.
34. Markle-Reid M, Browne G, Gafni A, et al. A cross-sectional study of the prevalence, correlates, and costs of falls in older home care clients 'at risk' for falling. *Can J Aging* 2010;29(1):119-137.
35. Weiss A, Brozgol M, Dorfman M, et al. Does the evaluation of gait quality during daily life provide insight into fall risk? A novel approach using 3-day accelerometer recordings. *Neurorehabil Neural Repair* 2013;27(8):742-752.
36. Weiss A, Herman T, Giladi N, Hausdorff JM. Objective assessment of fall risk in Parkinson's disease using a body-fixed sensor worn for 3 days. *PLoS ONE* 2014;9(5):e96675.
37. van Schooten KS, Pijnappels M, Rispen SM, Elders PJ, Lips P, van Dieën JH. Ambulatory fall-risk assessment: amount and quality of daily-life gait predict falls in older adults. *J Gerontol A Biol Sci Med Sci* 2015;70(5):608-615.
38. Rispen SM, van Schooten KS, Pijnappels M, Daffertshofer A, Beek PJ, van Dieën JH. Identification of fall risk predictors in daily life measurements: gait characteristics' reliability and association with self-reported fall history. *Neurorehabil Neural Repair* 2015;29(1):54-61.
39. Mactier K, Lord S, Godfrey A, Burn D, Rochester L. The relationship between real world ambulatory activity and falls in incident Parkinson's disease: influence of classification scheme. *Parkinsonism Relat Disord* 2015;21(3):236-242.
40. Brodie M, Lord S, Coppens M, Annegarn J, Delbaere K. Eight weeks remote monitoring using a freely worn device reveals unstable gait patterns in older fallers. *IEEE Trans Biomed Eng*. 2015;62(11):2588-2594.
41. Hiorth YH, Larsen JP, Lode K, et al. Impact of falls on physical activity in people with Parkinson's disease. *J Parkinsons Dis* 2016;6(1):175-182.
42. Snijders AH, Haaxma CA, Hagen YJ, Munneke M, Bloem BR. Freezer or non-freezer: clinical assessment of freezing of gait. *Parkinsonism Relat Disord* 2012;18(2):149-154.
43. Moore ST, Yungheer DA, Morris TR, et al. Autonomous identification of freezing of gait in Parkinson's disease from lower-body segmental accelerometry. *J Neuroeng Rehabil* 2013;10:19.
44. Tripoliti EE, Tzallas AT, Tsipouras MG, et al. Automatic detection of freezing of gait events in patients with Parkinson's disease. *Comput Methods Programs Biomed* 2013;110(1):12-26.

45. Weiss A, Herman T, Giladi N, Hausdorff JM. New evidence for gait abnormalities among Parkinson's disease patients who suffer from freezing of gait: insights using a body-fixed sensor worn for 3 days. *J Neural Transm* (Vienna, Austria: 1996) 2015;122(3):403-410.
46. Lord S, Galna B, Verghese J, Coleman S, Burn D, Rochester L. Independent domains of gait in older adults and associated motor and nonmotor attributes: validation of a factor analysis approach. *J Gerontol A Biol Sci Med Sci* 2013;68(7):820-827.
47. Lord S, Galna B, Rochester L. Moving forward on gait measurement: toward a more refined approach. *Mov Disord* 2013;28(11):1534-1543.
48. Mollenhauer B, Rochester L, Chen-Plotkin A, Brooks D. What can biomarkers tell us about cognition in Parkinson's disease? *Mov Disord* 2014;29(5):622-633.
49. Del Din S, Godfrey A, Galna B, Lord S, Rochester L. Free-living gait characteristics in ageing and Parkinson's disease: impact of environment and ambulatory bout length. *J Neuroeng Rehabil* 2016;13:46.
50. Salarian A, Russmann H, Vingerhoets FJ, et al. Gait assessment in Parkinson's disease: toward an ambulatory system for long-term monitoring. *IEEE Trans Biomed Eng* 2004;51(8):1434-1443.
51. Esser P, Dawes H, Collett J, Feltham MG, Howells K. Validity and inter-rater reliability of inertial gait measurements in Parkinson's disease: a pilot study. *J Neurosci Methods* 2012;205(1):177-181.
52. Esser P, Dawes H, Collett J, Feltham MG, Howells K. Assessment of spatio-temporal gait parameters using inertial measurement units in neurological populations. *Gait Posture* 2011;34(4):558-560.
53. Del Din S, Godfrey A, Rochester L. Validation of an accelerometer to quantify a comprehensive battery of gait characteristics in healthy older adults and Parkinson's disease: toward clinical and at home use. *IEEE J Biomed Health Inform* 2016;20(3):838-847.
54. Trojaniello D, Cereatti A, Pelosin E, et al. Estimation of step-by-step spatio-temporal parameters of normal and impaired gait using shank-mounted magneto-inertial sensors: application to elderly, hemiparetic, parkinsonian and choreic gait. *J Neuroeng Rehabil* 2014;11:152.
55. Trojaniello D, Ravaschio A, Hausdorff JM, Cereatti A. Comparative assessment of different methods for the estimation of gait temporal parameters using a single inertial sensor: application to elderly, post-stroke, Parkinson's disease and Huntington's disease subjects. *Gait Posture* 2015;42(3):310-316.
56. Brodie MA, Coppens MJ, Lord SR, et al. Wearable pendant device monitoring using new wavelet-based methods shows daily life and laboratory gaits are different. *Med Biol Eng Comput* 2016;54(4):663-674.
57. Weiss A, Sharifi S, Plotnik M, van Vugt JP, Giladi N, Hausdorff JM. Toward automated, at-home assessment of mobility among patients with Parkinson disease, using a body-worn accelerometer. *Neurorehabil Neural Repair* 2011;25(9):810-818.
58. Cancela J, Pastorino M, Arredondo MT, et al. Gait assessment in Parkinson's disease patients through a network of wearable accelerometers in unsupervised environments. *Annual International Conference Proceedings of IEEE EMBS IEEE Engineering in Medicine and Biology Society Annual Conference* 2011:2233-2236.
59. Cancela J, Pastorino M, Arredondo MT, Nikita KS, Villagra F, Pastor MA. Feasibility study of a wearable system based on a wireless body area network for gait assessment in Parkinson's disease patients. *Sensors* (Basel, Switzerland) 2014;14(3):4618-4633.
60. Weiss A, Herman T, Giladi N, Hausdorff JM. Association between community ambulation walking patterns and cognitive function in patients with Parkinson's disease: further insights into motor-cognitive links. *Parkinson's Dis* 2015;2015:547065.
61. Herman T, Weiss A, Brozgol M, Giladi N, Hausdorff JM. Gait and balance in Parkinson's disease subtypes: objective measures and classification considerations. *J Neurol* 2014;261(12):2401-2410.
62. Zampieri C, Salarian A, Carlson-Kuhta P, Nutt JG, Horak FB. Assessing mobility at home in people with early Parkinson's disease using an instrumented Timed Up and Go test. *Parkinsonism Relat Disord* 2011;17(4):277-280.
63. Smith E, Walsh L, Doyle J, Greene B, Blake C. The reliability of the quantitative timed up and go test (QTUG) measured over five consecutive days under single and dual-task conditions in community dwelling older adults. *Gait Posture* 2016;43:239-244.
64. Mancini M, El-Gohary M, Pearson S, et al. Continuous monitoring of turning in Parkinson's disease: rehabilitation potential. *NeuroRehabilitation* 2015;37(1):3-10.
65. El-Gohary M, Pearson S, McNames J, et al. Continuous monitoring of turning in patients with movement disability. *Sensors* (Basel, Switzerland) 2013;14(1):356-369.
66. Lord S, Godfrey A, Galna B, Mhiripiri D, Burn D, Rochester L. Ambulatory activity in incident Parkinson's: more than meets the eye? *J Neurol* 2013;260(12):2964-2972.
67. van Nimwegen M, Speelman AD, Smulders K, et al. Design and baseline characteristics of the ParkFit study, a randomized controlled trial evaluating the effectiveness of a multifaceted behavioral program to increase physical activity in Parkinson patients. *BMC Neurol* 2010;10:70.
68. Rochester L, Chastin SF, Lord S, Baker K, Burn DJ. Understanding the impact of deep brain stimulation on ambulatory activity in advanced Parkinson's disease. *J Neurol* 2012;259(6):1081-1086.
69. Chastin SFM, Granat MH. Methods for objective measure, quantification and analysis of sedentary behaviour and inactivity. *Gait Posture* 2010;31(1):82-86.
70. Dontje ML, de Greef MH, Speelman AD, et al. Quantifying daily physical activity and determinants in sedentary patients with Parkinson's disease. *Parkinsonism Relat Disord* 2013;19(10):878-882.
71. Chastin SFM, Baker K, Jones D, Burn D, Granat MH, Rochester L. The pattern of habitual sedentary behavior is different in advanced Parkinson's disease. *Mov Disord* 2010;25(13):2114-2120.
72. Cavanaugh JT, Ellis TD, Earhart GM, Ford MP, Foreman KB, Dibble LE. Capturing ambulatory activity decline in Parkinson's disease. *J Neurol Phys Ther* 2012;36(2):51-57.
73. Cavanaugh JT, Ellis TD, Earhart GM, Ford MP, Foreman KB, Dibble LE. Toward understanding ambulatory activity decline in Parkinson disease. *Phys Ther* 2015;95(8):1142-1150.
74. Lim I, van Wegen E, Jones D, et al. Does cueing training improve physical activity in patients with Parkinson's disease? *Neurorehabil Neural Repair* 2010;24(5):469-477.
75. Giuffrida JP, Riley DE, Maddux BN, Heldman DA. Clinically deployable Kinesia technology for automated tremor assessment. *Mov Disord* 2009;24(5):723-730.
76. Cancela J, Pastorino M, Tzallas AT, et al. Wearability assessment of a wearable system for Parkinson's disease remote monitoring based on a body area network of sensors. *Sensors* (Basel, Switzerland) 2014;14(9):17235-17255.
77. Orendurff MS, Schoen JA, Bernatz GC, Segal AD, Klute GK. How humans walk: bout duration, steps per bout, and rest duration. *Journal of rehabilitation research and development* 2008; 45(7):1077-1089.
78. Barry G, Galna B, Lord S, Rochester L, Godfrey A. Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics. *Gait Posture* 2015;42(4):594-597.
79. Evenson KR, Goto MM, Furberg RD. Systematic review of the validity and reliability of consumer-wearable activity trackers. *Int J Behav Nutr Phys Act* 2015;12(1):159.
80. Taraldsen K, Chastin SFM, Riphagen II, Vereijken B, Helbostad JL. Physical activity monitoring by use of accelerometer-based body-worn sensors in older adults: a systematic literature review of current knowledge and applications. *Maturitas* 2012;71(1):13-19.
81. Storm FA, Heller BW, Mazza C. Step detection and activity recognition accuracy of seven physical activity monitors. *PloS ONE* 2015;10(3):e0118723.
82. Picerno P, Cereatti A, Cappozzo A. A spot check for assessing static orientation consistency of inertial and magnetic sensing units. *Gait Posture* 2011;33(3):373-378.
83. Godfrey A, Lara J, Munro CA, et al. Instrumented assessment of test battery for physical capability using an accelerometer: a feasibility study. *Physiol Meas* 2015;36(5):N71-N83.
84. Cheng Z, Li P, Wang J, Guo S. Just-in-Time code offloading for wearable computing. *IEEE Trans Emerg Top Comput* 2015;3(1):74-83.



85. Steins D, Sheret I, Dawes H, Esser P, Collett J. A smart device inertial-sensing method for gait analysis. *J Biomech* 2014;47(15):3780-3785.
86. Tsanas A, Little MA, McSharry PE, Ramig LO. Accurate telemonitoring of Parkinson's disease progression by noninvasive speech tests. *IEEE Trans Biomed Eng* 2010;57(4):884-893.
87. Piro NE, Baumann L, Tengler M, Piro L, Blechschmidt-Trapp R. Telemonitoring of patients with Parkinson's disease using inertia sensors. *Appl Clin Inform* 2014;5(2):503-511.
88. Brouillette RM, Foil H, Fontenot S, et al. Feasibility, reliability, and validity of a smartphone based application for the assessment of cognitive function in the elderly. *PLoS ONE* 2013;8(6):e65925.
89. Liddle J, Ireland D, McBride SJ, et al. Measuring the lifespan of people with Parkinson's disease using smartphones: proof of principle. *JMIR mHealth and uHealth* 2014;2(1):e13.
90. Vayena E, Tasioulas J. Adapting standards: ethical oversight of participant-led health research. *PLoS Med* 2013;10(3):e1001402.
91. Kelly P, Marshall SJ, Badland H, et al. An ethical framework for automated, wearable cameras in health behavior research. *Am J Prev Med* 2013;44(3):314-319.
92. Heldman DA, Giuffrida JP, Chen R, et al. The modified bradykinesia rating scale for Parkinson's disease: reliability and comparison with kinematic measures. *Mov Disord* 2011;26(10):1859-1863.
93. Fisher JM, Hammerla NY, Rochester L, Andras P, Walker RW. Body-worn sensors in Parkinson's disease: evaluating their acceptability to patients. *Telemed J E Health* 2016;22(1):63-69.
94. Prudon B, Duncan GW, Khoo TK, Yarnall AJ, Anderson KN. Primary sleep disorder prevalence in patients with newly diagnosed Parkinson's disease. *Mov Disord* 2014;29(2):259-262.
95. Bossenbroek L, Kosse N, Ten Hacken N, Gordijn M, Van der Hoeven J, De Greef M. Validation of the DynaPort MiniMod during sleep: a pilot study. *Percept Mot Skills* 2010;111(3):936-946.
96. Godfrey A, Culhane KM, Lyons GM. Comparison of the performance of the activPAL Professional physical activity logger to a discrete accelerometer-based activity monitor. *Med Eng Phys* 2007;29(8):930-934.
97. Larkin L, Nordgren B, Purtill H, Brand C, Fraser A, Kennedy N. Criterion validity of the ActivPAL activity monitor for sedentary and physical activity patterns in people who have rheumatoid arthritis [published online ahead of print December 4, 2015]. *Phys Ther* 2015.
98. Dijkstra B, Kamsma Y, Zijlstra W. Detection of gait and postures using a miniaturised triaxial accelerometer-based system: accuracy in community-dwelling older adults. *Age Ageing* 2010;39(2):259-262.
99. Kangas M, Vikman I, Wiklander J, Lindgren P, Nyberg L, Jamsa T. Sensitivity and specificity of fall detection in people aged 40 years and over. *Gait Posture* 2009;29(4):571-574.
100. Pansera M, Estrada JJ, Pastor L, Cancela J, Greenlaw R, Arredondo MT. Multi-parametric system for the continuous assessment and monitoring of motor status in Parkinson's disease: an entropy-based gait comparison. *Annual International Conference Proceedings of IEEE EMBS IEEE Engineering in Medicine and Biology Society Annual Conference* 2009:1242-1245.
101. Salarian A, Russmann H, Vingerhoets FJ, Burkhard PR, Aminian K. Ambulatory monitoring of physical activities in patients with Parkinson's disease. *IEEE Trans Biomed Eng* 2007;54(12):2296-2299.
102. Bouten CV, Verboeket-van de Venne WP, Westerterp KR, Verduin M, Janssen JD. Daily physical activity assessment: comparison between movement registration and doubly labeled water. *J Appl Phys (Bethesda, MD: 1985)* 1996;81(2):1019-1026.
103. Benka Wallen M, Franzen E, Nero H, Hagstromer M. Levels and Patterns of Physical Activity and Sedentary Behavior in Elderly People With Mild to Moderate Parkinson Disease. *Phys Ther* 2015;95(8):1135-1141.
104. Peterson NE, Sirard JR, Kulbok PA, DeBoer MD, Erickson JM. Validation of accelerometer thresholds and inclinometry for measurement of sedentary behavior in young adult university students. *Res Nurs Health* 2015;38(6):492-499.
105. White DK, Wagenaar RC, Ellis T. Monitoring activity in individuals with Parkinson disease: a validity study. *J Neurol Phys Ther* 2006;30(1):12-21.
106. Schmidt AL, Pennypacker ML, Thrush AH, Leiper CI, Craik RL. Validity of the StepWatch Step Activity Monitor: preliminary findings for use in persons with Parkinson disease and multiple sclerosis. *J Geriatr Phys Ther* (2001) 2011;34(1):41-45.
107. Galna B, Lord S, Burn DJ, Rochester L. Progression of gait dysfunction in incident Parkinson's disease: impact of medication and phenotype. *Mov Disord* 2015;30(3):359-367.